BioArctic AB Class B BIOA B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 293.00
- Day Range
- SEK 287.20–293.80
- 52-Week Range
- SEK 257.00–364.40
- Bid/Ask
- SEK 287.20 / SEK 287.60
- Shares Outstanding
- 88.74M
- Market Cap
- SEK 25.51B
- Volume/Avg
- 82,950 / 134,886
Key Statistics
- Price/Earnings (Normalized)
- 243.73
- Price/Sales
- 25.51
- Dividend Yield (Trailing)
- 0.70%
- Dividend Yield (Forward)
- 0.70%
- Dividend Payment Schedule
- Jun
- Total Yield
- 0.70%
Company Profile
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 150
- Website
- https://www.bioarctic.se
Valuation
|
Metric
|
BIOA B
|
|---|---|
Price/Earnings (Normalized) | 243.73 |
Price/Book Value | 12.66 |
Price/Sales | 25.51 |
Price/Cash Flow | 85.20 |
Price/Earnings
BIOA B
Financial Strength
|
Metric
|
BIOA B
|
|---|---|
Quick Ratio | 2.97 |
Current Ratio | 3.99 |
Interest Coverage | 22.93 |
Quick Ratio
BIOA B
Profitability
|
Metric
|
BIOA B
|
|---|---|
Return on Assets (Normalized) | 4.06% |
Return on Equity (Normalized) | 5.18% |
Return on Invested Capital (Normalized) | 3.53% |
Return on Assets
BIOA B
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|lsQZ>v | LOCK|SQ>$ | $127B | |||
| Moderna Inc
MRNA
| LOCK|@N>gth | LOCK|!j? | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|CKFb<& | LOCK|wz$^# | $81B | |||
| argenx SE ADR
ARGX
| LOCK|l%tB>l | LOCK|<! | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?y?RnL$ | LOCK|^&l | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|vsVp^V | LOCK|z^!h^ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^qsY^LC> | LOCK|Q>N$? | $27B | |||
| Incyte Corp
INCY
| LOCK|k&J^<lD | LOCK|$s | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|vTWKYQ# | LOCK|zs | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|np&l^Pw | LOCK|D> | $14B |
United States